Forum Topic News
  • Conversation: Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study

    • December 10, 2018 11:39 AM GMT
    • Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study

      Biohaven Pharmaceutical Holding Company Ltd. today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for the acute treatment of migraine. Based upon this interim analysis (database cutoff of November 21, 2018) of Study BHV3000-201 (NCT03266588 or "Study 201") it appears that rimegepant may be safe and well tolerated with long-term dosing in patients with migraine. In this study, patients are allowed to treat migraine attacks of all severities (mild to severe) up to once daily for up to a full year.
      Migraine is both a widespread and disabling neurological disorder. The Migraine Research Foundation ranks migraine as the world's third most prevalent illness, affecting approximately 36 million people or 1 out of 4 households in the United States. And the Global Burden of Disease Study 2015 rates migraine as the seventh highest specific cause of disability worldwide. More than 90% of migraine sufferers are unable to work or function normally during an attack.
      Read more: https://prn.to/2QspYQ0

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč